SAN FRANCISCO — Using a composite endpoint scoring system, intravenous Actemra showed efficacy in noninfectious uveitis, according to research from the STOP-Uveitis study presented at the American Academy of Ophthalmology annual meeting.
Muhammad Hassan, MD, from Byers Eye Institute, Spencer Center for Vision Research, Stanford University, and colleagues randomly assigned patients with noninfectious uveitis to receive 4 mg/kg (G1) or 8 mg/kg (G2) of IV tocilizumab every 4 weeks for 6 months to determine the efficacy of IV Actemra (tocilizumab, Genentech) using a composite endpoint
Uncategorized